Next-Generation Long-Lasting Soluble CD4-D1 Domains as HIV Entry Inhibitors

CZV1-1-1 binds directly to Zika envelope domain III, blocks the binding of mouse anti-Zika neutralizing monoclonal antibodies, and neutralizes Zika virus growth in plaque reduction neutralization assays.

This molecule is the first nonpeptide surrogate and serves as a binding target for human antibodies that bind to a region on domain III of the Zika virus envelope protein.

CZV1-1-1 binds directly to Zika envelope domain III, blocks the binding of mouse anti-Zika neutralizing monoclonal antibodies, and neutralizes Zika virus growth in plaque reduction neutralization assays.

PROTAC-mediated degradation of HIV-1 Nef efficiently restores cell-surface CD4 and MHC-I expression and blocks HIV-1 replication.

Nef-directed PROTACs efficiently rescue Nef-mediated MHC-I and CD4 downregulation in T cells and suppress HIV-1 replication in PBMCs.

researchers have developed proteolysis targeting chimeras (PROTACs) for the targeted degradation of the HIV-1 Nef virulence factor.

University of Pittsburgh researchers have identified, humanized, and affinity enhanced a llama nanobody capable of targeting the human immunodeficiency virus-1 (HIV-1).

Affinity maturation of HuJ3 (humanized J3) has led to neutralization of many variants of HIV-1, exhibiting exceptional breath.

Following affinity maturation, these novel humanized antibodies (4E2) have demonstrated exceptional HIV-1 binding and neutralization potency and could be promising therapeutics to achieve viral suppression for HIV-infected people.